bioAffinity Technologies, Inc. (BIAF) Price & Analysis

Compare

164 Followers

BIAF Stock Chart & Stats

$2.09

-$0.03(-2.64%)

At close: Jan 08 4:00 PM EST

$2.09

-$0.03(-2.64%)

Day’s Range― - ―

52-Week Range$1.91 - $46.53

Previous CloseN/A

Volume17.91K

Average Volume (3M)5.91M

Market Cap

$9.40M

Enterprise Value$6.77M

Total Cash (Recent Filing)$802.84K

Total Debt (Recent Filing)$670.00K

Price to Earnings (P/E)―

Beta-2.78

Next Earnings

Nov 12, 2025

EPS Estimate

-2.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding4,498,709

10 Day Avg. Volume6,249,809

30 Day Avg. Volume5,911,951

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.24

Price to Sales (P/S)1.18

P/FCF Ratio-1.50

Enterprise Value/Market Cap0.72

Enterprise Value/Revenue0.88

Enterprise Value/Gross Profit2.95

Enterprise Value/Ebitda-0.61

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercial StrategyCyPath testing was up year-over-year with record testing volume in both June and July 2025, reflecting an accelerated commercialization strategy and increased clinical adoption.

Market ExpansionThe company is selling tests in several other states through referrals and word-of-mouth even before a broader commercial rollout.

Bears Say

Capital ConstraintsThe company's capital constraints remain a concern; therefore, analysts maintain a Hold rating as they believe the risk/reward is balanced.

Investment RecommendationThe inability to operate profitably and the need to raise additional capital gives analysts pause, leading to a recommendation not to purchase shares at this time.

Revenue And ProfitabilityAnalysts are lowering their 2025 and 2026 revenue estimates, and widening their 2025 and 2026 GAAP loss per share estimates.

bioAffinity Technologies, Inc. News

BioAffinity Technologies announces acceptance of Australian patent application

BioAffinity Technologies (BIAF) announced that the Australian Patent Office has accepted a patent application for the company’s proprietary...

15d ago

BIAF

BioAffinity Technologies receives notification of allowance for algorithm patent

BioAffinity Technologies (BIAF) announced it has received a notification of allowance from the United States Patent and Trademark...

27d ago

BIAF

BioAffinity Technologies regains compliance with Nasdaq

BioAffinity Technologies (BIAF) announced that it has received a written notice from Nasdaq stating that the company has...

28d ago

BIAF

BIAF Earnings this Week: How Will it Perform?

bioAffinity Technologies, Inc. (BIAF) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street...

2d ago

BIAF

bioAffinity Technologies Reports Surge in CyPath® Lung Tests

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an announcement. On November 5, 2025, bioAffinity Technologies announced significant...

7d ago

BIAF

bioAffinity Technologies Secures Australian Patent for Lung Health

bioAffinity Technologies, Inc. ( ($BIAF) ) just unveiled an announcement. On October 28, 2025, bioAffinity Technologies announced that...

15d ago

BIAF

bioAffinity Technologies Advances Non-Invasive Lung Cancer Diagnostic Study

bioAffinity Technologies, Inc. (($BIAF)) announced an update on their ongoing clinical study. bioAffinity Technologies, Inc. is spearheading a...

15d ago

BIAF

bioAffinity Technologies Advances Lung Cancer Detection with Innovative Study

bioAffinity Technologies, Inc. (($BIAF)) announced an update on their ongoing clinical study. bioAffinity Technologies, Inc. is conducting a...

15d ago

BIAF

bioAffinity Technologies Presents at CHEST 2025 Conference

bioAffinity Technologies, Inc. ( ($BIAF) ) has provided an announcement. On October 20, 2025, bioAffinity Technologies announced its...

22d ago

BIAF

bioAffinity Technologies Secures Patent for Lung Cancer Detection

bioAffinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 16, 2025, bioAffinity Technologies, Inc. announced...

27d ago

BIAF

bioAffinity Regains Nasdaq Compliance, Ensures Continued Trading

bioAffinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 15, 2025, bioAffinity Technologies announced it...

28d ago

BIAF

bioAffinity Technologies Announces $1.8M Direct Offering

An announcement from bioAffinity Technologies, Inc. ( ($BIAF) ) is now available. On October 8, 2025, bioAffinity Technologies,...

1M ago

BIAF

BioAffinity Technologies announces closing of $1.8M registered direct offering

bioAffinity Technologies (BIAF) announced it has closed the previously announced definitive agreements for the purchase and sale of...

1M ago

BIAF

BioAffinity Technologies announces $1.8M registered direct offering

bioAffinity Technologies (BIAF) announced that it has entered into definitive agreements for the purchase and sale of 720,000...

1M ago

BIAF

BIAF FAQ

What was bioAffinity Technologies, Inc.’s price range in the past 12 months?

bioAffinity Technologies, Inc. lowest stock price was $1.91 and its highest was $46.53 in the past 12 months.

What is bioAffinity Technologies, Inc.’s market cap?

bioAffinity Technologies, Inc.’s market cap is $9.40M.

When is bioAffinity Technologies, Inc.’s upcoming earnings report date?

bioAffinity Technologies, Inc.’s upcoming earnings report date is Nov 12, 2025 which is today.

How were bioAffinity Technologies, Inc.’s earnings last quarter?

Currently, no data Available

Is bioAffinity Technologies, Inc. overvalued?

According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does bioAffinity Technologies, Inc. pay dividends?

bioAffinity Technologies, Inc. does not currently pay dividends.

What is bioAffinity Technologies, Inc.’s EPS estimate?

bioAffinity Technologies, Inc.’s EPS estimate is -2.7.

How many shares outstanding does bioAffinity Technologies, Inc. have?

bioAffinity Technologies, Inc. has 4,498,709 shares outstanding.

What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?

Currently, no hedge funds are holding shares in BIAF

Company Description

bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. (BIAF) is a biotechnology company focused on developing innovative diagnostic and therapeutic solutions for cancer and other diseases. The company operates primarily in the healthcare sector, leveraging advanced technologies to enhance patient care and improve treatment outcomes. BIAF's core products include proprietary diagnostic platforms and targeted therapies that aim to detect and treat cancers more effectively, ultimately leading to personalized medicine approaches for patients.

bioAffinity Technologies, Inc. (BIAF) Earnings & Revenues

Historic Earnings Reports

BIAF Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"$72","-1":"-$1","17.25":"$17.25","35.5":"$35.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,17.25,35.5,53.75,72],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.2615384615384615,2.0730769230769233,1.8846153846153846,1.6961538461538463,1.5076923076923077,1.3192307692307692,1.1307692307692307,0.9423076923076923,0.7538461538461538,0.5653846153846154,0.3769230769230769,0.18846153846153824,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.2615384615384615,2.0730769230769233,1.8846153846153846,1.6961538461538463,1.5076923076923077,1.3192307692307692,1.1307692307692307,0.9423076923076923,0.7538461538461538,0.5653846153846154,0.3769230769230769,0.18846153846153824,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.45,2.2615384615384615,2.0730769230769233,1.8846153846153846,1.6961538461538463,1.5076923076923077,1.3192307692307692,1.1307692307692307,0.9423076923076923,0.7538461538461538,0.5653846153846154,0.3769230769230769,0.18846153846153824,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.6,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.6,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.7,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.25,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.88,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.1,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >